Image Source: AsiaOne
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime®Used For the Diagnosis of Intra-Abdominal Infection and Inflammatory Bowel DiseaseGlobeNewswireJanuary 27, 2020YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada for Drax Exametazine® (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling). Leukocyte labeling scintigraphy is a nuclear medicine imaging procedure that helps physicians localize an intra-abdominal infection and inflammatory bowel disease.
Source: AsiaOne